This bears reference to our earlier letter dated 05th September, 2025 regarding submission of Annual Report of our company for the Financial Year 2024-25. In this regard, we wish to ....
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories Limited) has resubmitted its 31st Annual Report for FY 2024-25 to BSE. The company had inadvertently uploaded it under 'Corporate Announcements' instead of 'Compliance' on September 5, 2025, and is now re-filing it under the correct category as required by Regulation 34 of SEBI (LODR) Regulations, 2015. The Annual Report includes the notice for the 31st AGM scheduled for September 29, 2025. Key agenda items include adoption of audited financials, reappointment of Managing Director Mr. Peeyush Kumar Aggarwal (who retires by rotation), approval for related party transactions up to Rs. 1,280 lakhs for FY 2025-26 (involving unsecured loans from promoter entities and director remuneration), and appointment of M/s Kundan Agrawal & Associates as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30).
This is essentially a procedural/clerical correction with no material business impact. Shareholders should note the upcoming AGM on September 29, 2025 and review the related party transaction proposals (especially loans from promoter-linked entities Omkam Global Capital, Omkam Developers, and MPS Informatics) and the new secretarial auditor appointment.